Literature DB >> 25656929

Overlap of CD44 expression between prostatic small cell carcinoma and acinar adenocarcinoma.

Chung-Chieh Wang1, Angelo M De Marzo2, Tamara L Lotan2, Jonathan I Epstein3.   

Abstract

Small cell carcinoma (SmCC) of the prostate is a rare and aggressive histologic subtype of the prostate cancer. It can sometimes mimic acinar adenocarcinoma with a high Gleason score (GS). A previous study showed that immunohistochemical staining for CD44 could help in the differential diagnosis of these 2 entities. In this study, we used 2 tissue microarrays including 63 cases of prostate cancer (18 pure SmCC, 37 pure acinar adenocarcinoma, and 8 mixed acinar adenocarcinoma and SmCC) to validate the value of CD44. When analyzed as a continuous variable, CD44 positivity was significantly higher in acinar adenocarcinoma with GS 8 than GS 9 to 10 (P = .027). However, the difference of CD44 expression between SmCC and acinar adenocarcinoma was insignificant. The current study fails to confirm the value of CD44 in differential diagnosis between prostatic SmCC and acinar adenocarcinoma.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acinar adenocarcinoma; CD44; Immunohistochemistry; Prostate cancer; Small cell carcinoma

Mesh:

Substances:

Year:  2014        PMID: 25656929     DOI: 10.1016/j.humpath.2014.12.007

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  2 in total

1.  Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas.

Authors:  Elham Kalantari; Mojgan Asgari; Seyedehmoozhan Nikpanah; Naghme Salarieh; Mohammad Hossein Asadi Lari; Zahra Madjd
Journal:  Pathol Oncol Res       Date:  2017-01-12       Impact factor: 3.201

Review 2.  Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.

Authors:  David S Priemer; Rodolfo Montironi; Lisha Wang; Sean R Williamson; Antonio Lopez-Beltran; Liang Cheng
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.